Disparities in Care and Barriers to Access for Patients with Advanced Prostate Cancer Podcast (2023)

Based on the documented need from the AUA Advanced Prostate Cancer Global Needs Assessment, the AUA is offering phase two of an educational series to update urologists and advanced practice providers (APPs) on the latest advancements in androgen deprivation therapy (ADT) and prostate cancer treatment. Part II will consist of two live webinars, one designed specifically for urologists and the other for APPs. The live virtual courses will feature a multidisciplinary panel engaging in a lively discussion on this topic. For a deeper dive into select topics in ADT and advanced prostate cancer care, the AUA will also produce two additional episodes for release on the AUAUniversity Podcast:

Disparities in Care and Barriers to Access for Patients with Advanced Prostate Cancer Podcast (2023)



This series is supported by independent educational grants from: 

Myovant Sciences LTD
Pfizer, Inc.

Target Audience

  • Urologists
  • Advanced Practice Providers (APPs)

Learning Objectives

At the conclusion of these activities, participants will be able to:

  1. Recognize current patterns of use for systemic therapies in patients with advanced prostate cancer.
  2. Identify disparities in access to care with respect to advanced prostate cancer treatment (ie. race, geography, socioeconomics).
  3. Understand opportunities to improve quality and compliance with ADT treatment across different treatment populations.
  4. Appreciate financial challenges that may be associated with current therapy options for advanced prostate cancer.
  5. Apply treatment approaches that improve patient adherence to ADT including use of oral and parenteral therapies.
Course summary
Available credit: 
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 Non-Physician Participation
Course opens: 
Course expires: 

Education Council Disclosures

PDF iconEducation Council Disclosures

COI Review Work Group Disclosures

PDF iconCOI Review Work Group Disclosures

AUA Office of Education Staff has nothing to disclose.

All relevant financial relationships have been mitigated.


Jay Raman, MD, FACS

has no relevant financial relationships to disclose at this time.
Podcast Co-Host(s)

Samuel Washington, MD

has a financial relationship (Other (Oncology)) with National Comprehensive Cancer Network;.
has a financial relationship (Scientific Study or Trial (Oncology)) with ConcertAI;.
has a financial relationship (Health Publishing (Oncology)) with UroToday;.
has a financial relationship (Consultant or Advisor (Oncology)) with Association of Community Cancer Centers;.


Learners will participate in this online educational activity by listening to the podcast and completing the post-test and evaluation. To claim CME credit for this enduring material, learners must complete the post-test, passing with 80% accuracy, and submit the program evaluation.

Estimated time to complete this activity: 0.50 hours

Release Date: October, 2023
Expiration Date: October, 2024


The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.


The American Urological Association designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.


It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.


All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider all financial relationships with any commercial interest during the previous 24 months. The AUA must determine if the individual’s relationships may influence the educational content and mitigate any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.


All disclosures will be reviewed by the AUA Conflict of Interest (COI) Review Work Group Chair and/or Vice Chair for identification of conflicts of interest. The AUA COI Review Work Group, working with Office of Education staff, will document the mechanism(s) for management and mitigation of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to mitigate conflict of interest:

  • Peer review for valid, evidence-based content by the AUA COI Review Work Group.
  • Attestation that clinical recommendations are evidence-based and free of commercial bias.
  • Introduction of a debate format (point-counterpoint)
  • Inclusion of moderated panel discussion with unbiased moderator
  • Publication of a parallel or rebuttal article for an article that is felt to be biased
  • Divestiture of the relationship by faculty
  • Recusal from controlling relevant aspects of planning
  • Selection of alternative faculty for specific topic


The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.

Available Credit

  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 Non-Physician Participation
Please login or register to take this course.